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Abstract  33 
The development of novel drugs for the treatment of leishmaniases continues to be crucial 34 
to overcome the severe impacts of these diseases on human and animal health. Several 35 
bioactivities have been described in extracts from macroalgae belonging to the Cystoseira 36 
genus. However, none of the studies has reported the chemical compounds responsible for the 37 
antileishmanial activity observed upon incubation of the parasite with the aforementioned 38 
extracts. Thus, this work aimed to isolate and characte ize the molecules present in a hexane 39 
extract of Cystoseira baccata that was found to be bioactive against Leishmania infantum in a 40 
previous screening effort. A bioactivity-guided fractionation of the C. baccata extract was 41 
carried out and the inhibitory potential of the isolated compounds was evaluated via the MTT 42 
assay against promastigotes and murine macrophages as well as direct counting against 43 
intracellular amastigotes. Moreover, the promastigote ultrastructure, DNA fragmentation and 44 
changes in the mitochondrial potential were assessed to unravel their mechanism of action. In 45 
this process, two antileishmanial meroditerpenoids, (3R)- and (3S)-tetraprenyltoluquinol 46 
(1a/1b) and (3R)- and (3S)-tetraprenyltoluquinone (2a/2b), were isolated. Compounds 1 and 47 
2 inhibited the growth of the L. infantum promastigotes (IC50 = 44.9 ± 4.3 and 94.4 ± 10.1 48 
µM, respectively), inducing cytoplasmic vacuolization and the presence of coiled 49 
multilamellar structures in mitochondria as well as an intense disruption of the mitochondrial 50 
membrane potential. Compound 1 decreased the intracellular infection index (IC50 = 25.0 ± 51 
4.1 µM), while compound 2 eliminated 50% of the intracellular amastigotes at a 52 
concentration > 88.0 µM. This work identified compound 2 as a novel metabolite and 53 
compound 1 as a biochemical isolated from Cystoseira algae displaying antileishmanial 54 
activity. Compound 1 can thus be an interesting scaffold for the development of novel 55 
chemotherapeutic molecules for canine and human visceral leishmaniases studies. This work 56 
reinforces the evidence of the marine environment as source of novel molecules. 57 
 58 
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BALB/c, albino mouse laboratory-bred strain of the house mouse; 67 
CC
50
, cytotoxic concentration that causes the death of 50% of the viable cells; 68 
COSY, correlation spectroscopy; 69 
DEPT, distortionless enhancement by polarization tra sfer spectrometry; 70 
FBS, fetal bovine serum;  71 
HMBC, heteronuclear multiple-bond correlation spectroscopy; 72 
HRESIMS; high-resolution electrospray ionisation mass spectrometry; 73 
HSQC, heteronuclear single-quantum correlation spectros opy; 74 
IC
50
, half-maximal inhibitory concentration;  75 
IR, infrared; 76 
LRESIMS, low-resolution electrospray ionisation mass spectrometry; 77 
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; 78 
NMR, nuclear magnetic resonance spectroscopy; 79 
NOESY, nuclear Overhauser effect spectroscopy; 80 
RCF, relative centrifugal force; 81 
SDS, sodium dodecyl sulfate; 82 
TLC, thin-layer chromatography; 83 
TMS, tetramethylsilane; 84 
UV, ultraviolet; 85 

















1. Introduction  88 
Leishmaniases are a group of infectious diseases cau ed by obligate intracellular 89 
protozoa of the Leishmania genus. Endemic in 98 tropical and subtropical countries and 90 
affecting 12 million people, leishmaniases may entail cutaneous, mucocutaneous and diffuse 91 
forms as well as the potentially fatal visceral form (Alvar et al., 2012). Visceral leishmaniasis 92 
causes considerable morbidity in 200-400 thousand individuals every year, with extreme 93 
suffering and financial loss, especially in the poorest populations of the Indian subcontinent 94 
(Mondal et al., 2014). Currently, leishmaniases aremong the most neglected tropical 95 
diseases, facing problems of resistance of the parasite to the available therapeutic molecules. 96 
The need for the discovery and development of alterna ive drugs allowing more efficient and 97 
effective treatments is thus quite urgent (Freitas-Junior et al., 2012).  98 
Nowadays, marine natural products are recognized as powerful reservoirs of novel, 99 
chemically diverse molecules with wide applicability to health sciences (Tempone et al., 100 
2011). Occurring worldwide, mainly in the rocky subtrates of the Mediterranean Sea and the 101 
adjoining Atlantic coasts, Cystoseira C. Agardh (1820) genus encompasses 39 species of 102 
brown macroalgae (Guiry and Guiry, 2015). Several bioactivities such as anti-inflammatory, 103 
antiproliferative, antioxidant (Mhadhebi et al., 2011), enzyme inhibitory (Ghannadi et al., 104 
2013), cytotoxic (Khanavi et al., 2010), antifungal (Lopes et al., 2013), antiviral (Ibraheem et 105 
al., 2012), antibacterial (Tajbakhsh et al., 2011) and antiprotozoal (Spavieri et al., 2010) have 106 
been detected in this algal genus. Despite the extensiv  chemical studies available for the 107 
Cystoseira genus, there have been only a few reports describing the antileishmanial potential 108 
effects of its crude extracts, and no information was found on the compounds responsible for 109 
the inhibitory effects on the Leishmania parasites (Amico, 1995; de Los Reyes et al., 2012). 110 
As part of ongoing research on the identification of antileishmanial compounds from the 111 
Cystoseira genus, this work describes the bioactivity-guided fractionation of the hexane 112 
extract from Cystoseira baccata and the effect of the extract, fractions and isolated 113 
compounds on the promastigote and amastigote forms f Leishmania infantum.  114 
 115 
2. Material and Methods 116 
2.1 General Experimental Procedures 117 
Optical rotations were measured in a JASCO DIP-370 digital polarimeter (Na filter, λ = 118 
588 nm). UV spectra were recorded using a UV/visible Shimadzu 1650-PC 119 
















spectrophotometer. 1H, 13C, DEPT, COSY, HSQC, HMBC and NOESY NMR spectra were 121 
recorded in a Bruker Avance III 500 spectrometer, operating at 500 and 125 MHz, to 1H and 122 
13C nuclei, respectively. CDCl3 (Aldrich) was used as the solvent with TMS as the int rnal 123 
standard. HRESIMS spectra were measured with a Bruker Daltonics MicroTOF QII 124 
spectrometer while LRESIMS spectra were recorded on a VG Platform II spectrometer. 125 
Silica gel (Merck, 230–400 mesh) and Sephadex LH-20 (Amersham Biosciences) were used 126 
for column chromatographic separation, while silica gel 60 PF254 (Merck) was used for 127 
analytical (0.25 mm) and preparative TLC (1.0 mm).  128 
 129 
2.2 Algal material 130 
Cystoseira baccata biomass was collected in July 2012 in Areosa, Viana do Castelo, 131 
Portugal (41º42’27.60’’N, 8º51’44.90’’W). After collection, biomass was cleaned and 132 
cryodesiccated. Voucher specimen (MB-1) was deposited within the Laboratory of the 133 
Marine Biotechnology Group - MarBiotech at the Centr  of the Marine Sciences of the 134 
University of Algarve (Faro, Portugal).  135 
 136 
2.3 Extraction and isolation of compounds 137 
Dried and powdered biomass (120 g) was exhaustively extracted with hexane in a Soxhlet 138 
apparatus. After evaporation of the solvent under reduced pressure, 1.3 g of crude extract 139 
were obtained. Part of this extract (0.6 g) was subject to column chromatography over SiO2 140 
eluted with hexane containing increasing amounts of EtOAc (up to 100%), followed with 141 
CHCl3 containing increasing amounts of MeOH (up to 100%), generating 13 fractions (1 – 142 
13). As fraction 10 (370.0 mg) displayed activity towards promastigote forms of L infantum, 143 
it was fractionated over SiO2 column, and eluted with hexane:EtOAc 1:1 yielding 6 sub-144 
fractions (A – F). Bioactive sub-fraction E (195 mg) was purified in a Sephadex LH-20 145 
column being eluted with hexane:CH2Cl2 1:4, CH2Cl2:Me2CO 3:2 and 1:1 (Cardellina II, 146 
1983) originating 4 groups (E1 – E4). Bioactive group E4 (65.3 mg) was subjected to 147 
preparative TLC (hexane-EtOAc, 7:3, twice) to afford compounds 1a/1b (23.2 mg; 0.30%) 148 
and 2a/2b (2.5 mg; 0.04%) (Fig.1). 149 
3R – tetraprenyltoluquinol (1a) and 3S – tetraprenyltoluquinol (1b). Yellowish oil; 1H 150 
NMR and 13C NMR (500 MHz, CDCl3) data, see Table 1; LRESIMS m/z 441 [M+H]
+ and 151 
















3R – tetraprenyltoluquinone (2a) and 3S – tetraprenyltoluquinone (2b). Colourless oil; 153 
[α]D
25 = + 0.06 (c 0.15, CHCl3); UV (MeOH) λmax (log ε) 352 (2.0), 248 (3.4) nm; IR (KBr) 154 
νmax 3400, 1670, 1480, 1180, 1060 cm-1; 1H and 13C NMR (500 MHz, CDCl3), see Table 1 155 
and Fig. 2; HRESIMS (positive mode) m/z 455.2776 [M+H]+ and 477.2604 [M+Na]+ (calcd 156 
for C28H39O5 and C28H38O5Na, 455.2797 and 477.2616, respectively). 157 
 158 
2.4. Parasites, mammalian cells and animal maintenance 159 
L. infantum strain (MHOM/PT/88/IMT-151) promastigotes were obtained from the 160 
cryobank of the Instituto de Higiene e Medicina Tropical (Universidade Nova de Lisboa, 161 
Portugal) and cultivated in M199 medium supplemented with 10% foetal bovine serum (FBS), 162 
penicillin (10 U/L), streptomycin (0.01 mg/L) and 2% of human male urine at 25 ºC. 163 
Peritoneal macrophages from BALB/c mice were cultivated in RPMI-1640 medium 164 
supplemented with 10% FBS, L-glutamine (2 mM), penicillin (50 U/L) and streptomycin 165 
(0.05 mg/L) at 37 ºC in humidified atmosphere with 5% CO2. BALB/c mice were obtained in 166 
the Animal Facility of the School of Medicine of São Paulo University – Brazil. These 167 
animals were maintained in accordance with the institutional guidelines regarding the welfare 168 
of experimental animals and with the approval of the Animal Ethics Committee of São Paulo 169 
University (322/12).  170 
 171 
2.5.  Activity against Leishmania promastigotes 172 
For the determination of the antileishmanial activity, L. infantum promastigotes in 173 
stationary phase (2×106 parasites/mL) were incubated with the hexane extract at a 174 
concentration of 250 µg/mL for 24h on 96-well plates. Using the same methodology, the 175 
fractions obtained during the bioactivity-guided fractionation were tested at a concentration 176 
of 50 µg/mL. At a later stage, compounds 1 and 2 were added at concentrations ranging from 177 
0.9 to 227.0 and 0.9 to 220.0 µM, respectively. Parasites treated with miltefosine at the half 178 
maximal inhibitory concentration (IC50 = 23.1 µM) were used as positive control. 179 
Promastigotes incubated with M199 medium were used a  negative control. Parasite viability 180 
was determined by the MTT colorimetric assay (Dutta e  l., 2005; Dal Picolo et al., 2014). 181 
Briefly, after incubation plates were centrifuged at 10 ºC, using an RCF of 1479 × g for 10 182 
min, washed three times with PBS, and supernatants discarded. Afterwards, 50 µL of MTT (5 183 
mg/mL in PBS) were added to each well and plates were re-incubated at 37 ºC for 2 h. Upon 184 
















to dissolve the formazan crystals. Absorbance was measured at 590 nm using a Thermo 186 
Scientifc Multiskan™ FC Microplate Photometer. Results were expressed in terms of parasite 187 
viability (%) relative to non-treated parasites and the half maximal inhibitory concentration 188 
(IC50; µM). 189 
 190 
2.6. Ultrastructural alterations of the promastigotes 191 
 L. infantum promastigotes in stationary phase (2 x 106 cells/mL) were incubated at 25 ºC 192 
for 24 h on 96-well plates with compounds 1 and 2 at their IC50 values, i.e. 44.9 µM of 94.4 193 
µM, respectively. Non-treated promastigotes were used as negative control. After incubation, 194 
the plate was centrifuged at 1479 × g for 10 min at 4 ºC, and washed with PBS three times. 195 
Pellets were fixed in 0.1% tannic acid dissolved in 2.0% glutaraldehyde in a 0.15 M 196 
phosphate buffer pH 7.2 and incubated for 1h at 4°C. These were afterwards contrasted in 1% 197 
osmium tetroxide and a 0.5% uranyl acetate solution for 12 h; then the samples were 198 
embedded in araldite resin (Yamamoto et al., 2015). Ultrathin sections (70 nm), obtained 199 
with a ultramicrotome Reichert and double contrasted with 2% uranyl acetate and 0.5% lead 200 
citrate, were examined using a JEOL 1010 transmission electron microscope.  201 
 202 
2.7. Promastigotes DNA integrity 203 
To detect whether the compounds induced fragmentatio  on L. infantum nuclear DNA, 204 
promastigote forms in stationary phase of growth (2 x 108 cells) were incubated with IC50 205 
concentrations of compounds 1 (44.9 µM), 2 (94.4 µM) and hydrogen peroxide (6.2 µM) as 206 
an inductor of DNA damage in parasites (Das et al., 2001) for 24 h at 25 ºC. Non-treated cells 207 
were used as control. After incubation, plates were c ntrifuged at 1479 × g for 10 min at 4 ºC, 208 
and the supernatants discarded. Parasites pellets wre extracted with a Macherey-Nagel 209 
nucleoSpin® Blood kit according with the manufacturer ecommendations and ran on a 2% 210 
agarose gel, 100 V for 90 min. 211 
 212 
2.8. Promastigote transmembrane mitochondrial potential 213 
In order to evaluate the influence of compound 1 on the promastigote mitochondrial 214 
membrane potential (∆Ψm), parasites in the stationary phase (2×106 parasites/mL) were 215 
incubated with compound 1 and miltefosine at their IC50 values (44.9 and 23.1 µM, 216 
















using the widefield automated microscope Mitoscreen Kit (BD Biosciences) according to the 218 
manufacturer’s recommendations (Levy et al., 2014; Yamamoto et al., 2015). Briefly, cells 219 
were incubated with working solution, containing the JC-1 (5,5,6,6-tetrachloro-1,1,3,3-220 
tetraethylbenzimidazolylcarbocyanine iodide) fluorochrome, for 15 min at 37 °C in an 221 
atmosphere of 5% CO2. ∆Ψm induces the uptake of JC-1 monomers into the functio al 222 
mitochondria. Once inside the organelle, JC-1 monomers aggregate, exhibiting high levels of 223 
red fluorescence and ∆Ψm is assessed through the determination of the presenc  of JC-1 224 
fluorochrome inside the mitochondria. ImageXpress® Micro XLS Widefield High-Content 225 
Analysis System and transfluor MetaXpress software were used to determine the presence of 226 
J-aggregates in nine sites per well and three wells p r treatment. ∆Ψm was expressed as a 227 
percentage of J-aggregates per cell. 228 
 229 
2.9. Cytotoxicity against murine macrophages 230 
To determine the compounds toxicity in vitro, murine peritoneal macrophages, were 231 
seeded in RPMI-1640 at a density of 106 cells/mL and incubated overnight at 37 ºC in 232 
humidified atmosphere with 5% CO2, allowing the cells to adhere to the plate background. 233 
Compounds 1 and 2 were tested for 24h at concentrations ranging from 0.9 to 227.0 and 0.9 234 
to 220.0 µM, respectively. Miltefosine control cells were incubated with RPMI-1640 medium 235 
at concentrations from 3.8 up to 490.7 µM. Cell viability was evaluated by the MTT 236 
colorimetric assay (Ferrari et al., 1990; Dal Picolo et al., 2014), as described above, for the 237 
determination of the activity against Leishmania promastigotes. Absorbance was measured at 238 
590 nm using a Thermo Scientific Multiskan™ FC Microplate Photometer. Results were 239 
expressed in terms of the cytotoxic concentration causing a 50% decrease in cell viability 240 
(CC50; µM) relative to non-treated cells (100 %). 241 
 242 
2.10. Activity against Leishmania intracellular amastigotes and NO production 243 
Peritoneal macrophages of BALB/c mice were collected by intraperitoneal lavage, seeded 244 
on 24-well plates (105 cells/mL) and incubated at 37ºC with 5% CO2 during 2h for cell 245 
attachment. Afterwards, L. infantum promastigotes in stationary phase were added to each246 
well at an infection ratio of 10 promastigotes per c ll, being further incubated at 37 ºC for 247 
24h. Infected macrophages were treated with compounds 1 and 2 at concentrations ranging 248 
from 7 to 90 µM to determine the corresponding IC50. Supernatants were collected for nitric 249 
















assessed upon Giemsa staining for determination of the infection index [% of infected 251 
macrophages × internalized amastigote forms / macrophage)] (Passero et al., 2015) and the 252 
inhibitory concentration allowing 50% reduction of the infection index (IC50) was estimated. 253 
Miltefosine was used as positive control. Culture supernatants of treated and control 254 
macrophages were used for NO determination that was performed using the Measure-iTTM 255 
High-Sensitivity Nitrite Assay Kit in accordance with the manufacturer's recommendations 256 
(Life Technologies). The NO concentration was determined using a calibration curve 257 
prepared with several known concentrations (2.75, 5.5, 11, 22, 33, 44 and 55 µM) of nitrite as 258 
standard. Results were expressed as NO production (µM) and compared with untreated 259 
infected and non-infected macrophages. The selectivity index (SI) was obtained by 260 
calculating the ratio of the CC50 of the macrophage by the IC50 of the intracellular 261 
amastigotes. 262 
 263 
2.11. Statistical analysis 264 
Bioassays results were expressed as mean ± standard error of the mean (SEM) of 265 
replicates samples from at least two independent assays. The IC50 values were calculated 266 
fitting the data as a non-linear regression using a dose-response inhibitory model, in the 267 
GraphPad Prism V 5.0 program. Student’s t-test was used to determine whether differences 268 
between means were significant at different levels (p < 0.05 and p < 0.01). 269 
3. Results and Discussion 270 
The hexane extract from the C. baccata was incubated with promastigote forms of L. 271 
infantum for 24h, and cell viability was determined by means of the MTT assay. As this 272 
extract decreased the viability of the parasite by 74% at a concentration of 250 µg/mL, it was 273 
selected for further study. Bioactivity-guided fractionation afforded compounds 1 and 2 274 
(Fig. 1).  275 
Compound 1 was obtained as an optically active oil [α]D = + 17.8° (CHCl3, c 2.7). 276 
Structural evidence was obtained by analysis of NMR (1H, 13C and DEPT 135°), HREIMS 277 
spectra and comparison with those data previously reported in the literature to (3R)-(1a) and 278 
(3S)-(1b) tetraprenyltoluquinol, previously isolated from C. baccata (Valls et al., 1993). In 279 
addition, some corrections in the attributions of chemical shifts of C-18 and C-19 in 13C 280 
NMR spectrum were carried out, based on the HMBC spectral analysis (Table 1). Compound 281 
















to be homogeneous on the TLC chromatograms, revealing that it is a mixture of closely 283 
related derivatives. The 1H NMR spectrum of compound 2 revealed some similarities with 284 
compound 1 - two peaks assigned to hydrogens of aromatic ring at δH 7.15 (d, J = 3.0 Hz, H-285 
3’) and 7.00 (d, J = 3.0 Hz, H-5’), one methoxyl group at δH 3.78 (s) as well as five singlets 286 
assigned to methyl groups at δH 1.20 (H-20), 1.25/1.26 (H-17), 1.13/1.11 (H-16), 1.09/1.04 287 
(H-18), and 0.91/0.83 (H-19). 13C and DEPT 135° NMR spectra confirmed the presence of 288 
aromatic ring due the peaks at range δC 151.9 – 114.6 (C-1’ – C-6’), and one methoxyl group 289 
at δC 55.7. Additionally, peaks assigned to a carbonyl group at δC 192.2/192.1 (C-1), to 290 
carbinolic carbons at δC 81.3/81.2 (C-3) and 71.0 (C-15) as well as an α,β-unsaturated 291 
carbonyl carbon at δC 153.3/154.3 (C-5), 133.5/134.0 (C-13) and 208.0/208.1 (C-12) were 292 
observed. Finally, HRESIMS showed the [M+H]+ and [M + Na]+ quasi-molecular ion peaks 293 
at m/z 455.2776 and 477.2604, respectively, indicating the molecular formula C28H38O5. The 294 
connectivity between hydrogens and carbon atoms was revealed by analysis of the HMBC 295 
spectrum as showed in Fig. 2. The correlations betwe n signals at δH 7.15 (H-3’) and 296 
2.56/2.57 (H-2) with δC 192.2/192.1 (C-1) as well as between δH 2.70 (H-4) with δC 81.3/81.2 297 
(C-3) and 133.5/134.0 (C-13) indicated that compound 2 contained one additional carbonyl 298 
group at C-1. Based on these results, it was possible to identify 2 as epimers of (3R)-(2a) and 299 
(3S)-(2b) tetraprenyltoluquinones.  300 
In vitro antiparasitic activity and cytotoxic studies of the compounds 1 and 2 were 301 
evaluated by the colorimetric MTT method against promastigote forms of L. infantum and 302 
murine macrophages, respectively (Table 2). Compound 1 displayed an IC50 value of 44.9 ± 303 
4.3 µM against promastigote forms of L. infantum. The cytotoxicity against mouse peritoneal 304 
macrophages (CC50 = 126.6 ± 21.1 µM) was similar to that of the refence drug, miltefosine 305 
(130.3 ± 17.2 µM). Compound 2 showed lower activity against the promastigote forms (IC50 306 
= 94.4 ± 10.1 µM), and higher toxicity to the mouse peritoneal macrophages (CC50 = 84.5 ± 307 
12.5 µM).   308 
To assess the alterations induced by the compounds o  the promastigotes forms of L. 309 
infantum, transmission electron microscopy images were acquired (Fig. 3). Important 310 
changes were observed with both treatments, including loss of the typical fusiform shape (Fig. 311 
3A). Ultrastructural analysis revealed morphologic changes in parasites treated with the IC50 312 
concentrations of both compounds 1 (Figs. 3B and 3C) and 2 (Figs. 3D and 3E). Moreover, 313 
cellular vacuolization was observed, which might be a consequence of cytoplasmic organelle 314 
















multilamellar structures within the mitochondria (Fig. 3C). These structures have been shown 316 
to be a consequence of starvation processes caused by deficient mitochondrial activity or 317 
autophagic mechanisms caused by the action of chemial compounds on these organelles 318 
(Lockshin and Zakeri, 2004). If left unchecked, both processes may result in the removal of 319 
the damaged organelles as well as cell death (Nishikawa et al., 2010). Previous studies have 320 
described similar structures in promastigotes of different Leishmania species treated with 321 
distinct natural products (Monte Neto et al., 2011). Compound 2 induced noticeable changes 322 
in the ultrastructure of the cell, in particular the occurrence of pyknotic nuclei, which was 323 
accompanied by the disappearance of the chromatin associated with the nuclear inner 324 
membrane (Fig. 3D).  325 
Overall, these compounds seem to induce parasite death through different mechanisms. 326 
Other reports have shown that Leishmania apoptosis occurs in response to different drugs 327 
(Holzmuller et al., 2002). In order to evaluate if the alterations observed in the nuclei were 328 
associated with DNA fragmentation and consequently with programmed cell death, 329 
promastigote DNA was analysed through horizontal electrophoresis. This analysis did not 330 
reveal any fragmentation of the genomic DNA when promastigote forms of L. infantum were 331 
treated with the IC50 concentrations of compounds 1 and 2 (Fig. 4A), suggesting that the 332 
observed cytotoxic effect might not be associated with programmed cell death. Although 333 
chromatin condensation culminating in nucleolytic pyknosis is usually accompanied by 334 
macronuclear DNA digestion, generating oligonucleosomal fragments of low molecular 335 
weight (Kobayashi and Endoh, 2003), non-nucleolytic pyknotic processes have also been 336 
described previously (Burgoyne, 1999).   337 
As Leishmania cells have a single mitochondrion, the proper functio ing of mitochondria, 338 
including the stability of their membrane potential, is vital for the survival of the parasite. 339 
This organelle is usually considered as a good indicator of cellular dysfunction and therefore 340 
is an interesting target for chemotherapeutic studies (Souza et al., 2009). Because the 341 
variation of the mitochondrial membrane potential (∆Ψm) in different Leishmania species 342 
exposed to various drugs has been reported (Britta et l., 2014) and that changes were 343 
observed in the morphology of the mitochondria of promastigotes treated with compound 1, 344 
the ∆Ψm in cells incubated with the latter chemical was evaluated. This was carried out in 345 
order to elucidate possible mechanisms of cell death induced by the compound displaying the 346 
most potent activity against L. infantum promastigotes. This parameter was determined by 347 
assessing the presence of JC-1 fluorochrome inside the mitochondria using a widefield 348 
















mitochondria. Once inside the organelle, JC-1 monomers aggregate, exhibiting high levels of 350 
red fluorescence. At the IC50, compound 1 induced a significant (p ≤ 0.01) decrease in 351 
fluorescence-emitting cells (133.3 ± 8.5 J-aggregats/well) as compared to non-treated (762.5 352 
± 36.7 J-aggregates/well) promastigotes (Fig. 4B), corresponding to a disruption of 83% of 353 
the ∆Ψm. This effect was higher than that observed with miltefosine (216.0 ± 22.6 J-354 
aggregates/well), which disrupted the ∆Ψm by only 72%. Interestingly, similar drops in ∆Ψm 355 
coupled with changes in the mitochondrial ultrastructure have also been detected when using 356 
an iron chelator against L. (V.) braziliensis (Mesquita-Rodrigues et al., 2013). 357 
When tested against L. infantum-infected macrophages the tetraprenyltoluquinol (1) 358 
applied at concentrations of 34 and 66 µM decreased the infection index by 64.5% and 66.3%, 359 
respectively, showing an IC50 of 25.0 ± 4.1 µM and a selectivity index of 5.04 against the 360 
peritoneal macrophages (Fig. 5A; Table 2). 361 
Only five compounds isolated from marine algae with antileishmanial activity have been 362 
reported previously (da Silva Machado et al., 2011; dos Santos et al., 2010, 2011; Soares et 363 
al., 2012). However, none of the studies was about Cystoseira macroalgae. Reported 364 
sesquiterpenes obtusol (IC50 = 9.4 µM; da Silva Machado et al., 2011) and elatol (IC50 = 13.5 365 
µM and 0.45 µM) from the red alga Laurencia dendroidea  (daSilva Machado et al., 2011; 366 
dos Santos et al., 2010) showed strong activity against L. amazonensis intracellular 367 
amastigotes. However, the triquinane sesquiterpene isolated from the same algae was 368 
significantly less effective (IC50 = 217.4 µM; da Silva Machado et al., 2011). In addition, 4-369 
acetoxydolastane and dolabelladienetriol, isolated from the brown alga Canistrocarpus 370 
cervicornis (IC50 = 12.3 µM; dos Santos et al., 2011) and Dictyota pfaffii (IC50 = 44.0 µM; 371 
Soares et al., 2012), respectively, were also tested against the same species and form of 372 
Leishmania. Therefore, the activity of compound 1 was in the range of that reported for the 373 
aforementioned diterpenes. 374 
 Despite the lower activity of compound 2 against promastigotes (IC50 = 94.4 ± 10.1), it 375 
was higher than the effect reported for triquinane (IC50 = 195.5 µM) on promastigotes. 376 
However, similarly to what has been reported for triquinane (da Silva Machado et al., 2011), 377 
the treatment with the tetraprenyltoluquinone (2) did not decrease the infection index (Fig. 378 
5A). 379 
During the infection by Leishmania, NO is released by macrophages to eliminate 380 
intracellular amastigotes (reviewed by de Almeida et l., 2003). In addition, NO production 381 
can be triggered by natural compounds, including those from algae (Robertson et al., 2015). 382 
















produced low or undetectable amounts of NO as compared to controls. The NO released 384 
when the lowest concentrations (8.4 and 17 µM) were applied to the cells was residual, 385 
suggesting that the leishmanicidal effect observed for 1 was not related to NO production by 386 
the host macrophages (Fig. 5B) and that these compounds did not display an 387 
immunomodulatory effect.  These results are in agreement with Silva Machado et al. (2011) 388 
who observed that triquinane, elatol and obtusol did not promote enhanced NO levels, 389 
indicating that leishmanicidal effect of these compunds might be mediated by a mechanism 390 
that does not involve the release of this signalling molecule by the host cell. 391 
In conclusion, this is the first report describing the identification of compounds from 392 
Cystoseira macroalgae displaying activity against Leishmania parasites. In addition, the 393 
isolation of tetraprenyltoluquinone (2) as a novel metabolite from algae of the Cystoseira 394 
genus is described. Concerning the particular chemical structure of these compounds, our 395 
data suggest that the presence of the carbonyl group in C-1 could play a role in the 396 
antileishmanial activity of the compounds 1 and 2. Although not as active as miltefosine, 397 
tetraprenyltoluquinol (1) displayed significant antileishmanial activity and could be 398 
considered as an interesting scaffold for the development of novel chemotherapeutic 399 
molecules for canine and human visceral leishmaniases studies. Furthermore, this work 400 
reinforces the evidence of the marine environment as source of novel molecules. 401 
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Fig. 1.  Structures of the tetraprenyltoluquinols (1a-1b) and tetraprenyltoluquinones (2a-2b) 541 
isolated from C. baccata 542 


















Fig. 2.  HMBC of the tetraprenyltoluquinones (2a-2b) isolated from C. baccata 546 
 547 


















Fig. 3. Effect of compounds 1 and 2 on the ultrastructure of L. infantum promastigotes. 551 
Parasites were treated with 1a/1b (44.9 µM) and treated with compound 2a/2b (94.4 µM). N 552 
– nucleus, FP - flagellar pocket, K – kinetoplast, M – mitochondrion, V – vacuole, * - 553 
disappearance of the chromatin associated with the nuclear inner membrane 554 


















Fig. 4. Effects of compounds 1 (Comp1) and 2 (Comp2) on the nuclear DNA fragmentation 558 
(A) and mitochondrial membrane potential (B) of L. infantum promastigotes. Parasites were 559 
treated with 1a/1b (44.9 µM) and 2a/2b (94.4 µM). Hydrogen peroxide (6.2 µM) (A) and 560 
miltefosine (23.1 µM) (B) and untreated parasites (A and B) were used as controls. *, p < 561 
0.05;  **, p < 0.01. 562 
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 565 
Fig. 5. Effect of compounds 1 and 2 on the L. infantum intracellular amastigotes (A) and on 566 
the nitric oxide production (mM) of the infected mouse peritoneal macrophages (B) after a 567 
24-h treatment with different concentrations (µM). Untreated non-infected macrophages 568 
(CTL+), untreated infected macrophages (CTL inf) and infected macrophages treated with a 569 
reference drug, miltefosine, were used as controls. 570 


















Table 1. 1H and 13C NMR data (500 and 125 MHz, CDCl3, δ/ppm) for compounds 1 (a/b) 574 
and 2 (a/b)  575 
Compound 1a 1b 2a 2b 
Position δC, type δH (J in Hz) δC, type δH (J in Hz) δC, type δΗ (J in Hz) δC, type δH (J in Hz) 
1 22.7, CH2 2.79, (m) 22.6, CH2 2.79, (m) 192.2, C - 192.1, C - 
2 32.5, CH2 1.80, (m) 33.6, CH2 1.80, (m) 47.8, CH2 2.56, (m) 48.6, CH2 2.57, (m) 
3 76.4, C - 76.2, C - 81.3, C - 81.2, C - 
4 43.6, CH2 2.66, (s) 45.2, CH2 2.66, (s) 44.1, CH2 2.70, (s) 44.8, CH2 2.70, (s) 
5 153.7, C - 154.5, C - 153.3, C - 154.3, C - 
6 44.3, CH2 2.57, (m) 44.7, CH2 2.57, (m) 44.1, CH2 2.60, (d, 4.0) 44.1, CH2 2.63, (d, 4.0) 
2.60, (m) 2.60, (m) 2.68, (d, 4.0) 2.68, (d, 4.0) 
7 44.8, C - 44.8, C - 44.9, C - 44.9, C - 
8 35.0, CH2 1.54, (m) 35.0, CH2 1.54, (m) 35.0, CH2 1.54, (m) 35.0, CH2 1.54, (m) 
1.73, (m) 1.73, (m) 1.73, (m) 1.73, (m) 
9 18.8, CH2 1.74, (m) 18.8, CH2 1.74, (m) 18.8, CH2 1.74, (m) 18.8, CH2 1.74, (m) 
10 29.3, CH2 1.46, (m) 29.3, CH2 1.46, (m) 29.4, CH2 1.40, (d, 13.0) 29.7, CH2 1.42, (d, 13.0) 
11 54.9, C - 54.9, C - 54.9, C - 54.9, C - 
12 208.5, C - 208.9, C - 208.0, C - 208.1, C - 
13 132.9, C - 133.3, C - 133.5, C - 134.0, C - 
14 39.4, CH2 2.45, (d, 15.0) 39.9, CH2 2.45, (d, 15.0) 39.4, CH2 2.54, (d, 15.0) 39.6, CH2 2.54, (d, 15.0) 
2.73, (d, 15.0) 2.73, (d, 15.0) 2.59, (d, 15.0) 2.59, (d, 15.0) 
15 70.8, C - 71.1, C - 71.0, C - 71.0, C - 
16 28.8, CH3 1.12, (s) 28.8, CH3 1.14, (s) 29.1, CH3 1.11, (s) 29.1, CH3 1.13, (s) 
17 30.5, CH3 1.24, (s) 31.6, CH3 1.19, (s) 30.8, CH3 1.25, (s) 31.3, CH3 1.26, (s) 
18 21.1, CH3 1.09, (s) 21.1, CH3 1.03, (s) 21.1, CH3 1.04, (s) 21.1, CH3 1.09, (s) 
19 22.4, CH3 0.91, (s) 22.5, CH3 0.83, (s) 22.4, CH3 0.83, (s) 22.5, CH3 0.91, (s) 
20 24.1, CH3 1.28, (s) 24.5, CH3 1.28, (s) 23.9, CH3 1.20, (s) 24.2, CH3 1.20, (s) 
1' 145.2, C - 145.3, C - 167.8, C - 167.8, C - 
2' 120.4, C - 120.4, C - 119.6, C - 119.6, C - 
3' 111.1, CH 6.45, (d, 3.0) 111.2, CH 6.46, (d, 3.0) 114.6, CH 7.15, (d, 3.0) 114.6, CH 7.16, (d, 3.0) 
4' 152.6, C - 152.6, C - 151.9, C - 151.9, C - 
5' 115.2, CH 6.59, (d, 3.0) 115.3, CH 6.60, (d, 3.0) 104.5, CH 7.00, (d, 3.0) 104.5, C 7.01, (d, 3.0) 
6' 127.0, C - 127.2, C - 126.5, C - 126.5, C - 
Me-6' 16.6, CH3 2.16, (s) 16.8, CH 2.17, (s) 16.2, CH3 2.21, (s) 16.4, CH3 2.23, (s) 
OMe-4' 55.6, CH3 3.73, (s) 55.6, CH 3.74, (s) 55.7, CH3 3.78, (s) 55.7, CH3 3.78, (s) 
















Table 2. Effect of the compounds 1 and 2 against L. infantum promastigotes and intracellular 577 








1 44.9 ± 4.3 25.0 ± 4.1 126.6 ± 21.1 5.04 
2   94.4 ± 10.1 > 88.0   84.5 ± 12.5 <0.96 
Miltefosine 23.1  ± 0.0 20.3 ± 1.3 130.3 ± 17.2 6.42 
aIC50 - Half maximal inhibitory concentration in µM; 
bCC50 - Cytotoxic concentration that causes the death of 
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• Tetraprenyltoluquinols and tetraprenylquinones from Cystoseira baccata. 
• Tetraprenyltoluquinols displayed antileishmanial activity  
• Tetraprenyltoluquinols induce alterations on promastigotes morphology. 
• Tetraprenyltoluquinol disrupt the Leishmania mitochondrial membrane potential.  
 
